LXRX logo

Lexicon Pharmaceuticals, Inc. (LXRX) EBITDA

Annual EBITDA:

-$184.28M-$13.09M(-7.64%)
December 31, 2024

Summary

  • As of today, LXRX annual EBITDA is -$184.28 million, with the most recent change of -$13.09 million (-7.64%) on December 31, 2024.
  • During the last 3 years, LXRX annual EBITDA has fallen by -$97.48 million (-112.31%).
  • LXRX annual EBITDA is now -206.07% below its all-time high of $173.74 million, reached on December 31, 2019.

Performance

LXRX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherLXRXincome statement metrics

Quarterly EBITDA:

-$12.04M-$15.95M(-407.67%)
September 30, 2025

Summary

  • As of today, LXRX quarterly EBITDA is -$12.04 million, with the most recent change of -$15.95 million (-407.67%) on September 30, 2025.
  • Over the past year, LXRX quarterly EBITDA has increased by +$51.53 million (+81.07%).
  • LXRX quarterly EBITDA is now -104.73% below its all-time high of $254.22 million, reached on September 30, 2019.

Performance

LXRX Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherLXRXincome statement metrics

TTM EBITDA:

-$57.34M+$51.53M(+47.33%)
September 30, 2025

Summary

  • As of today, LXRX TTM EBITDA is -$57.34 million, with the most recent change of +$51.53 million (+47.33%) on September 30, 2025.
  • Over the past year, LXRX TTM EBITDA has increased by +$153.22 million (+72.77%).
  • LXRX TTM EBITDA is now -127.49% below its all-time high of $208.56 million, reached on September 30, 2019.

Performance

LXRX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherLXRXincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

LXRX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-7.6%+81.1%+72.8%
3Y3 Years-112.3%+47.6%+39.9%
5Y5 Years-206.1%+69.8%+72.7%

LXRX EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-112.3%at low-407.7%+81.1%at high+72.8%
5Y5-Year-206.1%at low-407.7%+81.1%at high+72.8%
All-TimeAll-Time-206.1%at low-104.7%+81.1%-127.5%+72.8%

LXRX EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
-$12.04M(-407.7%)
-$57.34M(+47.3%)
Jun 2025
-
$3.91M(+115.3%)
-$108.87M(+35.2%)
Mar 2025
-
-$25.50M(-7.6%)
-$168.00M(+10.5%)
Dec 2024
-$184.28M(-7.6%)
-$23.71M(+62.7%)
-$187.68M(+10.9%)
Sep 2024
-
-$63.57M(-15.1%)
-$210.56M(-7.2%)
Jun 2024
-
-$55.22M(-22.2%)
-$196.47M(-6.0%)
Mar 2024
-
-$45.19M(+3.0%)
-$185.35M(-8.3%)
Dec 2023
-$171.20M(-70.6%)
-$46.59M(+5.8%)
-$171.20M(-10.6%)
Sep 2023
-
-$49.48M(-12.2%)
-$154.78M(-20.7%)
Jun 2023
-
-$44.10M(-42.1%)
-$128.29M(-18.7%)
Mar 2023
-
-$31.03M(-2.8%)
-$108.09M(-7.7%)
Dec 2022
-$100.33M(-15.6%)
-$30.18M(-31.3%)
-$100.33M(-5.2%)
Sep 2022
-
-$22.99M(+3.8%)
-$95.38M(-0.1%)
Jun 2022
-
-$23.90M(-2.7%)
-$95.25M(-6.7%)
Mar 2022
-
-$23.27M(+7.7%)
-$89.27M(-2.8%)
Dec 2021
-$86.80M(+49.0%)
-$25.22M(-10.3%)
-$86.80M(-26.8%)
Sep 2021
-
-$22.86M(-27.6%)
-$68.46M(+19.9%)
Jun 2021
-
-$17.92M(+13.9%)
-$85.46M(+34.1%)
Mar 2021
-
-$20.80M(-202.3%)
-$129.62M(+23.9%)
Dec 2020
-$170.35M(-198.1%)
-$6.88M(+82.7%)
-$170.35M(+18.8%)
Sep 2020
-
-$39.86M(+35.8%)
-$209.75M(-348.7%)
Jun 2020
-
-$62.08M(-0.9%)
$84.33M(-34.5%)
Mar 2020
-
-$61.53M(-33.0%)
$128.77M(-25.9%)
Dec 2019
$173.74M(+274.4%)
-$46.28M(-118.2%)
$173.74M(-16.7%)
Sep 2019
-
$254.22M(+1541.6%)
$208.56M(+408.2%)
Jun 2019
-
-$17.64M(-6.4%)
-$67.67M(+14.8%)
Mar 2019
-
-$16.57M(-44.6%)
-$79.38M(+20.3%)
Dec 2018
-$99.60M(+20.4%)
-$11.46M(+48.0%)
-$99.59M(+15.6%)
Sep 2018
-
-$22.01M(+25.0%)
-$118.00M(+5.3%)
Jun 2018
-
-$29.34M(+20.2%)
-$124.59M(+2.8%)
Mar 2018
-
-$36.79M(-23.2%)
-$128.22M(+2.3%)
Dec 2017
-$125.12M(+7.9%)
-$29.86M(-4.4%)
-$131.18M(+0.7%)
Sep 2017
-
-$28.59M(+13.3%)
-$132.14M(+5.7%)
Jun 2017
-
-$32.98M(+17.0%)
-$140.12M(+2.1%)
Mar 2017
-
-$39.75M(-29.0%)
-$143.17M(-5.4%)
Dec 2016
-$135.80M(-1258.8%)
-$30.82M(+15.7%)
-$135.80M(-29.4%)
Sep 2016
-
-$36.57M(-1.5%)
-$104.98M(-9.0%)
Jun 2016
-
-$36.03M(-11.2%)
-$96.28M(-11.0%)
Mar 2016
-
-$32.38M(-16.2%)
-$86.70M(-6.9%)
Dec 2015
$11.72M(+115.0%)
-
-
Sep 2015
-
-$27.86M(-5.3%)
-$81.07M(-0.4%)
Jun 2015
-
-$26.45M(-8.3%)
-$80.79M(-3.5%)
Mar 2015
-
-$24.42M(-946.7%)
-$78.04M(+0.3%)
Dec 2014
-$78.31M(+23.0%)
-$2.33M(+91.5%)
-$78.31M(+19.7%)
Sep 2014
-
-$27.58M(-16.3%)
-$97.57M(+1.7%)
Jun 2014
-
-$23.71M(+4.0%)
-$99.29M(+3.5%)
Mar 2014
-
-$24.69M(-14.3%)
-$102.91M(-1.2%)
Dec 2013
-$101.72M(-7.8%)
-$21.60M(+26.3%)
-$101.72M(+2.1%)
Sep 2013
-
-$29.30M(-7.2%)
-$103.90M(-7.4%)
Jun 2013
-
-$27.32M(-16.3%)
-$96.76M(-5.6%)
Mar 2013
-
-$23.50M(+1.2%)
-$91.66M(+2.8%)
Dec 2012
-$94.34M
-$23.78M(-7.3%)
-$94.34M(+6.0%)
Sep 2012
-
-$22.16M(+0.3%)
-$100.40M(+0.0%)
DateAnnualQuarterlyTTM
Jun 2012
-
-$22.22M(+15.1%)
-$100.41M(+0.6%)
Mar 2012
-
-$26.18M(+12.3%)
-$101.05M(+0.6%)
Dec 2011
-$101.64M(-16.0%)
-$29.84M(-34.6%)
-$101.64M(-7.6%)
Sep 2011
-
-$22.17M(+3.0%)
-$94.48M(-2.0%)
Jun 2011
-
-$22.86M(+14.6%)
-$92.62M(-0.2%)
Mar 2011
-
-$26.77M(-18.0%)
-$92.47M(-3.6%)
Dec 2010
-$87.61M(-4.6%)
-$22.68M(-11.6%)
-$89.29M(-2.6%)
Sep 2010
-
-$20.32M(+10.5%)
-$87.06M(-0.0%)
Jun 2010
-
-$22.71M(+3.7%)
-$87.06M(-1.7%)
Mar 2010
-
-$23.59M(-15.3%)
-$85.58M(-2.1%)
Dec 2009
-$83.80M(+5.4%)
-$20.45M(-0.7%)
-$83.80M(-1.7%)
Sep 2009
-
-$20.31M(+4.3%)
-$82.37M(+3.0%)
Jun 2009
-
-$21.24M(+2.6%)
-$84.94M(+3.5%)
Mar 2009
-
-$21.80M(-14.6%)
-$88.02M(+0.7%)
Dec 2008
-$88.61M(-34.9%)
-$19.02M(+16.9%)
-$88.61M(-3.1%)
Sep 2008
-
-$22.89M(+5.9%)
-$85.93M(-7.1%)
Jun 2008
-
-$24.32M(-8.7%)
-$80.26M(-12.3%)
Mar 2008
-
-$22.38M(-36.9%)
-$71.44M(-8.8%)
Dec 2007
-$65.69M(-49.2%)
-$16.34M(+5.1%)
-$65.69M(-7.1%)
Sep 2007
-
-$17.22M(-11.1%)
-$61.35M(-13.3%)
Jun 2007
-
-$15.50M(+6.8%)
-$54.15M(-1.7%)
Mar 2007
-
-$16.63M(-38.6%)
-$53.22M(-19.2%)
Dec 2006
-$44.03M(-80.0%)
-$12.00M(-19.7%)
-$44.63M(-86.0%)
Sep 2006
-
-$10.02M(+31.2%)
-$23.99M(+4.4%)
Jun 2006
-
-$14.57M(-81.3%)
-$25.10M(-13.5%)
Mar 2006
-
-$8.04M(-193.0%)
-$22.12M(+9.6%)
Dec 2005
-$24.46M(+30.9%)
$8.64M(+177.7%)
-$24.46M(+22.1%)
Sep 2005
-
-$11.13M(+4.1%)
-$31.41M(-0.1%)
Jun 2005
-
-$11.60M(-11.7%)
-$31.38M(+5.8%)
Mar 2005
-
-$10.38M(-710.7%)
-$33.32M(+5.9%)
Dec 2004
-$35.42M(+30.8%)
$1.70M(+115.3%)
-$35.42M(+24.0%)
Sep 2004
-
-$11.10M(+18.0%)
-$46.59M(+1.8%)
Jun 2004
-
-$13.54M(-8.4%)
-$47.46M(+3.1%)
Mar 2004
-
-$12.48M(-31.8%)
-$48.96M(+4.3%)
Dec 2003
-$51.18M(+2.7%)
-$9.47M(+20.9%)
-$51.18M(+4.2%)
Sep 2003
-
-$11.97M(+20.4%)
-$53.44M(+5.0%)
Jun 2003
-
-$15.04M(-2.3%)
-$56.27M(-3.6%)
Mar 2003
-
-$14.70M(-25.2%)
-$54.32M(-3.3%)
Dec 2002
-$52.58M(-51.7%)
-$11.73M(+20.7%)
-$52.58M(-2.4%)
Sep 2002
-
-$14.80M(-13.0%)
-$51.36M(-19.8%)
Jun 2002
-
-$13.09M(-1.1%)
-$42.87M(-4.7%)
Mar 2002
-
-$12.96M(-23.2%)
-$40.95M(-8.2%)
Dec 2001
-$34.66M(-5.5%)
-$10.51M(-66.8%)
-$37.86M(-1.2%)
Sep 2001
-
-$6.30M(+43.6%)
-$37.42M(-6.0%)
Jun 2001
-
-$11.18M(-13.2%)
-$35.31M(-18.3%)
Mar 2001
-
-$9.87M(+2.0%)
-$29.84M(-42.5%)
Dec 2000
-$32.86M(-200.9%)
-$10.07M(-140.5%)
-$20.95M(-92.6%)
Sep 2000
-
-$4.19M(+26.7%)
-$10.87M(-62.7%)
Jun 2000
-
-$5.71M(-485.6%)
-$6.69M(-585.6%)
Mar 2000
-
-$975.10K
-$975.10K
Dec 1999
-$10.92M(-46.9%)
-
-
Dec 1998
-$7.44M(-44.1%)
-
-
Dec 1997
-$5.16M
-
-

FAQ

  • What is Lexicon Pharmaceuticals, Inc. annual EBITDA?
  • What is the all-time high annual EBITDA for Lexicon Pharmaceuticals, Inc.?
  • What is Lexicon Pharmaceuticals, Inc. annual EBITDA year-on-year change?
  • What is Lexicon Pharmaceuticals, Inc. quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for Lexicon Pharmaceuticals, Inc.?
  • What is Lexicon Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
  • What is Lexicon Pharmaceuticals, Inc. TTM EBITDA?
  • What is the all-time high TTM EBITDA for Lexicon Pharmaceuticals, Inc.?
  • What is Lexicon Pharmaceuticals, Inc. TTM EBITDA year-on-year change?

What is Lexicon Pharmaceuticals, Inc. annual EBITDA?

The current annual EBITDA of LXRX is -$184.28M

What is the all-time high annual EBITDA for Lexicon Pharmaceuticals, Inc.?

Lexicon Pharmaceuticals, Inc. all-time high annual EBITDA is $173.74M

What is Lexicon Pharmaceuticals, Inc. annual EBITDA year-on-year change?

Over the past year, LXRX annual EBITDA has changed by -$13.09M (-7.64%)

What is Lexicon Pharmaceuticals, Inc. quarterly EBITDA?

The current quarterly EBITDA of LXRX is -$12.04M

What is the all-time high quarterly EBITDA for Lexicon Pharmaceuticals, Inc.?

Lexicon Pharmaceuticals, Inc. all-time high quarterly EBITDA is $254.22M

What is Lexicon Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?

Over the past year, LXRX quarterly EBITDA has changed by +$51.53M (+81.07%)

What is Lexicon Pharmaceuticals, Inc. TTM EBITDA?

The current TTM EBITDA of LXRX is -$57.34M

What is the all-time high TTM EBITDA for Lexicon Pharmaceuticals, Inc.?

Lexicon Pharmaceuticals, Inc. all-time high TTM EBITDA is $208.56M

What is Lexicon Pharmaceuticals, Inc. TTM EBITDA year-on-year change?

Over the past year, LXRX TTM EBITDA has changed by +$153.22M (+72.77%)
On this page